Maddrey Willis C
Department of Internal Medicine, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas, USA.
Rev Gastroenterol Disord. 2005;5 Suppl 1:S3-9.
This article explores the rationale for use of antibiotics in the treatment of hepatic encephalopathy, discusses the role of antibiotics relative to other therapeutic approaches, and considers the reasons that limit the use of the antibiotics most commonly prescribed for the management of hepatic encephalopathy in the United States. Although the scientific rationale for the use of antibiotics in hepatic encephalopathy is well founded, the clinical evidence for their benefits is rather limited. There is no doubt that many antibiotics cause a decrease in intraluminal production of ammonia. However, the commonly prescribed antibiotics are also associated with a variety of adverse effects. None of the antibiotics typically used for hepatic encephalopathy is adequately tolerated in the target patient population. The clinical evidence to date does not support the first-line use of currently available antibiotics in the treatment of hepatic encephalopathy. To improve upon current antibiotic offerings for hepatic encephalopathy, an antibiotic should provide broad-spectrum coverage against both aerobic and anaerobic bacteria, effectively control neuropsychiatric signs and symptoms, and be extremely well tolerated in the target population. An antibiotic fulfilling these criteria would constitute an advance in therapy for hepatic encephalopathy.
本文探讨了使用抗生素治疗肝性脑病的理论依据,讨论了抗生素相对于其他治疗方法的作用,并考虑了限制美国最常用于治疗肝性脑病的抗生素使用的原因。尽管使用抗生素治疗肝性脑病的科学依据充分,但支持其益处的临床证据相当有限。毫无疑问,许多抗生素会减少肠腔内氨的产生。然而,常用的抗生素也与多种不良反应相关。目前用于肝性脑病的抗生素在目标患者群体中均未得到充分耐受。迄今为止的临床证据不支持将目前可用的抗生素作为治疗肝性脑病的一线用药。为了改进目前用于治疗肝性脑病的抗生素,一种抗生素应能对需氧菌和厌氧菌提供广谱覆盖,有效控制神经精神症状和体征,并且在目标人群中具有极高的耐受性。满足这些标准的抗生素将构成肝性脑病治疗的一项进展。